Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Anti-Infective Incentives: GAIN, LPAD Won’t Be Enough HHS-Commissioned Report Finds

This article was originally published in RPM Report

Executive Summary

The continuing government interest in incentives for antibacterial development got a boost from an unexpected quarter in June. A report commissioned by HHS calls for a broad package of incentives to stimulate continued investment in new anti-infectives.


Related Content

Antibiotic Incentive Legislation: Can Reimbursement Horn In?
GAIN Begins (Part 1): FDA Completes Turnaround On Antibiotic R&D
The Popularity of “Special Pop”: Antibiotics Incentives and PDUFA V


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts